Legal Opinion
Sanofi-Aventis v. Pfizer Inc.
Court of Appeals for the Federal Circuit
Decided November 5, 2013No. 2012-1345PublishedCited by 2 opinions
1Opinion of the Court
NEWMAN, Circuit Judge.
Sanofi-Aventis (“Sanofi”) appeals the decision of the United States Patent and Trademark Office (“PTO”) Board of Patent Appeals and Interferences (“the Board”), 2 awarding priority of invention to Pfizer Inc. (“Pfizer”) based on the following interference count:
Count 3. The isolated protein of 6,268,-480 claim 4;
Or
The isolated polynucleotide of 5,710,023 claim 1, selection (b) (an isolated polynucleotide comprising a nucleotide sequence of SEQ ID NO:3 from nucleotide 103 to nucleotide 1242).
Nucleotides 103 to 1242 constitute the protein-encoding portion of the…
2Cases cited10 opinions
- Hybritech Incorporated v. Monoclonal Antibodies, Inc.Court of Appeals for the Federal Circuit · 1986
- Amgen, Inc., Plaintiff/cross-Appellant v. Chugai Pharmaceutical Co., Ltd., and Genetics Institute, Inc.Court of Appeals for the Federal Circuit · 1991
- Burroughs Wellcome Co. v. Barr Laboratories, Inc., and Novopharm, Inc. And Novopharm, Ltd.Court of Appeals for the Federal Circuit · 1994
- Invitrogen Corp. (Formerly Known as Life Technologies, Inc.) v. Clontech Laboratories, Inc.Court of Appeals for the Federal Circuit · 2005
- Peter B. Cooper v. David GoldfarbCourt of Appeals for the Federal Circuit · 1998
5 more not listed; retrieve them via the Exa API.
3Cited by2 opinions
- Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc.Court of Appeals for the Federal Circuit · 2017
- Yeda Research and Development Co., Ltd. v. Abbott Gmbh & Co. KgDistrict Court, District of Columbia · 2015